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VCAM-1 expression on dystrophic muscle vessels has a critical role in the
recruitment of human blood–derived CD133! stem cells
after intra-arterial transplantation
Manuela Gavina, Marzia Belicchi, Barbara Rossi, Linda Ottoboni, Fabio Colombo, Mirella Meregalli, Maurizio Battistelli, Laura Forzenigo,
Piero Biondetti, Federica Pisati, Daniele Parolini, Andrea Farini, Andrew C. Issekutz, Nereo Bresolin,
Franco Rustichelli, Gabriela Constantin, and Yvan Torrente
Recently our group demonstrated the
myogenic capacity of human CD133! cells
isolated from peripheral blood when deliv-
ered in vivo through the arterial circula-
tion into the muscle of dystrophic scid/
mdx mice. CD133! stem cells express the
adhesion molecules CD44, LFA-1, PSGL-1,
"4-integrins, L-selectin, and chemokine
receptor CCR7. Moreover these cells ad-
here in vitro to VCAM-1 spontaneously
and after stimulation with CCL19. Impor-
tantly, after muscle exercise, we found
that the expression of VCAM-1 is strongly
up-regulated in dystrophic muscle ves-
sels, whereas the number of rolling and
firmly adhered CD133! stem cells signifi-
cantly increased. Moreover, human dys-
trophin expression was significantly in-
creased when muscle exercise was
performed 24 hours before the intra-
arterial injection of human CD133! cells.
Finally, treatment of exercised dystrophic
mice with anti–VCAM-1 antibodies led to
a dramatic blockade of CD133! stem cell
migration into the dystrophic muscle. Our
results show for the first time that the
expression of VCAM-1 on dystrophic
muscle vessels induced by exercise con-
trols muscle homing of human CD133!
stem cells, opening new perspectives for
a potential therapy of muscular dystro-
phy based on the intra-arterial delivery of
CD133! stem cells. (Blood. 2006;108:
2857-2866)
© 2006 by The American Society of Hematology
Introduction
Attempts to repair muscle damage in patients with Duchenne
muscular dystrophy (DMD) by transplanting myogenic progenitors
directly into muscles are hampered by the problem of cell survival
and the limited migration of these cells in the muscles. The delivery
of myogenic stem cells to the sites of muscle lesions through the
systemic circulation is a potential alternative approach to treat this
disease, but injected cells may become trapped intravenously in
other organs (eg, liver, spleen, lung) so that only a small portion
enters the muscle microvasculature and migrates to dystrophic
muscle. Our recent work supports the idea that stem cells can reach
the site of muscle regeneration and can contribute to muscle repair
and to replenishment of the satellite cell pool after intra-arterial
injection, suggesting that this technique might be particularly
suited for treating muscle dystrophy.1,2 This protocol succeeded
primarily because of the widespread distribution of donor stem
cells through the muscle capillary network, a distinct advantage of
this strategy over previous approaches. Elucidation of the mecha-
nisms involved in the muscle homing of stem cells will aid the
development of a potential therapy for muscular dystrophy based
on the systemic delivery of stem cells. It has been shown recently
that VLA-4–VCAM-1 interactions efficiently mediate rolling and
arrest in vivo in blood vessels from bone marrow or under
pathologic conditions characterized by an activated endothelium.3-5
In the present study, we focused our attention on the molecular
mechanisms involved in human CD133! cells homing to dystro-
phic muscle and efficiently mediating their transplantation.
Materials and methods
Isolation and characterization of human blood–derived CD133!
cell fraction for FACS analysis
Human circulating CD133! cells were isolated from blood mononucleated
cells, as previously described.1 The enrichment of CD133! cells was
followed by a second round of cell sorting for the CD133 antigen with a
dual-laser FACSVantage SE (Becton Dickinson, Franklin Lakes, NJ).
Sorted CD133! cells were double labeled with anti–CD133-phycoerythrin
(anti–CD133-PE) (Miltenyi Biotech, Bergisch Gladbach, Germany), anti–
VLA4-FITC, anti–CD44-FITC, anti–LFA1-FITC, anti–L-selectin–FITC
(BD Pharmingen, San Diego, CA), anti–PSGL1-FITC (MBL International,
Woburn, MA), anti–CCR3-FITC, anti–CCR5-FITC, anti–CCR7-FITC,
anti–CXCR3-FITC, and anti–CXCR4-FITC (R&D Systems, Minneapolis,
MN). Isotype control was performed using fluorescein isothiocyanate
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(FITC)–conjugated mouse IgG1, R-phycoerythrin (R-PE)–conjugated rat
IgG2a. To ensure the quality of our analysis, we also investigated sorted
CD133" cells for the expression of molecules, as previously indicated. We
also characterized the adhesion molecules and chemokines receptor expres-
sion of sorted CD133! cells after stimulation with 5 ng TNF-# in RPMI
1640 medium (Gibco, Invitrogen, Carlsbad, CA) enriched with insulin, 20
ng/mL epidermal growth factor (EGF), and 10 ng/mL basic fibroblastic
growth factor (bFGF). The cells were analyzed 4 to 5 hours after
stimulation and after overnight incubation with TNF-#.
In vitro adhesion assay on ICAM-1 and VCAM-1
We evaluated the functionality of LFA-1 and VLA-4 expressed by CD133!
cells using an in vitro spontaneous adhesion assay for human ICAM-1 and
VCAM-1 (R&D Systems).6 After isolation, sorted CD133! cells were
resuspended in PBS, CaCl2, MgCl2 1 mM, and 10% FCS (pH 7.2) at
2.5 $ 106/mL, and 25 %L of this suspension was plated on 18-well glass
slides for 30 minutes. The slides were coated with recombinant 1 %g/mL
ICAM-1 and 1 %g/mL VCAM-1 (R&D Systems), as previously described.6
Five microliters of CCL19/MIP3& (R&D Systems) was added (1 %M) to
the cell-containing wells for 3 minutes at 37°C. This chemokine has been
shown to induce the adhesion of human lymphocytes to endothelial cells or
endothelial cell adhesion ligands. Cells were fixed in 1.5% glutaraldehyde
for 20 minutes. The number of adherent cells in a 0.2-mm2 field was
counted using cell-counting software.
Selectin chimera binding assays
The functionality of PSGL-1 expressed on sorted blood-derived CD133!
and CD133" cells was demonstrated with a cytofluorimetric assay.
Approximately 5$ 105 cells were resuspended in 100 %L standard medium
(SM [DMEM, 0.1% BSA, 0.1% NaN3]) and were incubated for 30 minutes
at 4°C with E- and P-selectin chimeras (R&D Systems). Cells were washed
twice, resuspended in 100 %L SM, and incubated with anti–human IgG
FITC (diluted 1:32; Sigma, St Louis, MO) for 20 minutes at 4°C. After 2
washes in SM, cells were pelleted and resuspended in fresh DMEM
immediately before FACS analysis. Nonspecific staining was established by
the addition of EDTA (10 mM) to staining reactions conduced with the
selectin chimeras.
In vivo staining of endothelial adhesion molecules
To characterize the adhesion molecules expressed by murine muscle
vessels, we analyzed 3 groups (n ' 5 each) of 3-month-old scid/mdx mice:
group 1, mice under basal conditions; group 2, mice 4 to 5 hours after
stimulation with 1 %g TNF-# injected intravenously; group 3, mice after
muscle stress from 1 hour of swimming and analysis of adhesion molecule
expression 24 hours later. Monoclonal antibodies (mAbs) anti–E-selectin
(RME-1), anti–P-selectin (RMP-1), anti–MAdCAM-1 (MECA-367), anti–
ICAM-1 (YN1.1.7.4), anti–VCAM-1 (M.K.2.7), and isotype-matched
control antibodies were labeled using the Alexa Fluor 568 labeling kit
(Molecular Probes, Eugene, OR). Striate muscle vessels were visualized
using intravital microscopy, as described.1 Intravital visualization of the
Alexa Fluor 568 (Molecular Probes) staining was confirmed by fluores-
cence analysis of the cryosectioned hind limbs of each treated animal.
Immunocytochemistry for the expression of CD31 and #SMA was also
carried out to identify venules and arterioles, respectively. Intravital
microscopy images were captured with a BXW0WI microscope (Olympus,
Tokyo, Japan) equipped with an Olympus Achroplan water immersion
objective (20$/0.5 NA; focal distance, 3.3 mm).
Intravital microscopy
With the intravital microscopy model,7 we verified the muscle homing and
vascular adhesion properties of CD133! stem cells into the pectoral and
iliopsoas muscles of scid/mdx mice after muscle exercise (n ' 6) and after
administration of anti–VCAM-1 mAb (n' 6). Animals were anesthetized,
and the pectoral muscle was analyzed with an intravital microscope
(BX50WI; Olympus, Tokyo, Japan). A dextran dye (155 kDa; Sigma) was
injected to visualize the blood vessels. CD133! stem cells (106) were
fluorescently labeled with green CMFDA (5-chloromethylfluorescein diac-
etate; Molecular Probes) and injected by a digital pump at flow rate of 0.13
to 1 %L/s.
Characterization of muscle homing of CD133! stem cells
by HMPAO labeling
We tested the muscle selectivity of human circulating CD133! cells by
labeling them with technetium Tc 99m-labeled hexamethylpropylene amine
oxime (HMPAO), a radioactive marker previously described.8 Cells were
incubated for 2 hours at 37°C in RPMI medium supplemented with 1
%Ci/mL (0.037 MBq) HMPAO. Labeling efficiency was measured with a
dose calibrator (Atomlab 100; Biodex Medical, Shirley, NY). Cell vitality
was assessed by trypan blue and by double staining with propidium iodide
(PI) and annexin V. HMPAO-labeled CD133! (10 $ 105) or CD133" cells
were injected into the right femoral artery of 2-month-old scid/mdx mice in
basal condition (n' 5 each) and after swimming (n' 5 each). We
compared the distribution of radioactivity of the first series of experiments
with animals pretreated intraperitoneally with 250 %g selective blocking
antibodies against VCAM-1 (n' 4) and ICAM-1 (n' 4) (generous gifts
from Eugene C. Butcher, Laboratory of Immunology and Vascular Biology,
Department of Pathology, Stanford University School of Medicine, Stan-
ford, CA) 1 hour before stem cell injection. Animals were killed 24 hours
later, tissue from muscle, lung, kidney, liver, and brain was collected, and
radioactive content was measured in a &-counter (LS1801; Beckman
Coulter, Hialeah, FL) as previously described.8
Microfil perfusion
PkH2-labeled CD133! cells (5$ 105) were injected into the right femoral
artery of scid/mdx mice in basal conditions (n' 3) and 24 hours after
exercise (n ' 3). After cell injection, the mice were perfused with 10 mL
PBS and then 10 mL liquid silicon rubber (Microfil; Flow Tech, Carver,
MA). Hind limbs of treated mice were isolated in toto and placed under
refrigeration at 4°C overnight to allow polymerization. On the following
day, specimens were carefully dissociated and placed in a 50% mixture of
water and glycerin. At successive 24-hour intervals, the glycerin concentra-
tion was raised to 75%, then to 85%, and finally to pure glycerin. Statistical
analysis using the Student t test was also performed. Immunofluorescence
images were captured with a DMIRE2 microscope (Leica Microsystems,
Cambridge, United Kingdom) and a Leica DC350 camera. The microscope
was equipped with a 40$/0.75 NA dry objective. Images were acquired and
processed with Leica Qfluoro software.
Labeling of CD133! cells with iron oxide
To better characterize the migratory capacity of CD133! cells in mouse
dystrophic animal models, we used live cell tracking methods such as
magnetic resonance imaging (MRI) after labeling with nanoparticles of iron
oxide (Endorem; Guerbet, Sulzbach, Germany).9,10 Human CD133! stem
cells were labeled with 250 %g/mL Endorem (Guerbet) in RPMI 1640
medium enriched with 20 ng/mL EGF and 10 ng/mL bFGF for 12 or 24
hours. We tested different cell suspensions (100 000, 50 000, 20 000, 5000,
500 cells) in 1.7% gelatin. For in vivo experiments, CD133! cells were
injected intra-arterially in the scid/mdx dystrophic animal model and were
visualized with MRI. Images were obtained using a 4.7-T spectrometer
(Burker, KooWeeRup, VIC, Australia) equipped with a surface coil made in
house. Single sagittal, coronal, and transversal images were obtained by a
fast gradient-echo sequence to localize the subsequent T2-weighted trans-
verse images, as measured by a standard turbo spin-echo sequence. The
same muscles monitored by MRI were isolated and characterized by
immunohistochemistry for the expression of CD133 antigen and Prussian
blue staining.9
Histochemistry and immunocytochemistry of injected
dystrophic muscles
For human dystrophin detection, unexercised (n' 5) and exercised (n' 6)
scid/mdx mice were injected intra-arterially with 500 000 human CD133!
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stem cells, as previously described.1 Sixty days later, muscle sections were
characterized using the anti–human nuclear lamin A/C (Novocastra, 1:200),
anti–human dystrophin (1:50; Chemicon, Temecula, CA), anti–#-smooth
muscle actin (DAKO, Carpinteria, CA), and anti-CD31 (1:100; Chemicon)
antibodies, as previously described.1
Results
Characterization of adhesion molecules and
chemokine receptors
To evaluate the migratory capacity of human circulating CD133!
cells, we first studied by flow cytometry the adhesion molecules
and chemokine receptors expressed on their surfaces. In these
experiments, we sorted CD133! and CD133" cells, and we
characterized both populations by flow cytometry analysis.
Sorted CD133! cells (99% ( 1% [mean ( SD]) coexpressed
CD44 and LFA-1. In particular, we observed 2 subpopulations
of CD133 on the basis of LFA-1dim and LFA-1bright expression. In
addition, 83% ( 2% of sorted CD133! cells expressed PSGL-1,
44% ( 3% expressed VLA-4, and 60% ( 5% expressed L-
selectin. Chemokine receptor analysis showed very low expres-
sion of CXCR3 and CXCR4 (4% ( 3%), whereas 44% ( 5.4%
of CD133! cells were positive for CCR7. Less than 2% of sorted
CD133! cells expressed CCR3 (1.6% ( 1.3%) or CCR5
(1.7%( 1.5%). We observed that sorted CD133" cells expressed
98%( 1% CD44, 87%( 1% LFA-1, 63.5%( 1% L-selectin,
53.5%( 1% CCR7, 19%( 1% CXCR3, 3.5%( 1% CXCR4,
1.2%( 1% CCR3, and 0.09%( 1% CCR5. In contrast to CD133!
cells, very low expression of VLA-4 (0.6%( 0.5%) and reduced
expression of PSGL-1 (7.5%( 1%) were observed on sorted
CD133" cells. Although the expression of chemokine receptors and
adhesion molecules was regulated in leukocytes by the inflamma-
tory microenvironment, human circulating CD133! cells did not
seem to be particularly influenced by this condition. In fact, after 5
and 20 hours of stimulation with TNF-# in culture medium, only
the percentage of cells expressing L-selectin was decreased from
60% to 4%. The other adhesion molecules and chemokine recep-
tors showed no modification in their expression as a result of
exposure to TNF-# (Figure 1). All these data demonstrate that
human CD133! cells express a complete pattern of adhesion
molecules and chemokine receptor CCR7, an important molecule
usually involved in the activation and migration of leukocytes
under physiologic and pathologic conditions.
Evaluation of adhesion capability of CD133! cells in vitro
The adhesion capacity of CD133! cells to integrin ligands was
evaluated in vitro by adhesion assays to VCAM-1 and ICAM-1
before and after stimulation with MIP3& (CCL19, a ligand for
CCR7 receptor). Rapid adhesion assays showed that CD133! cells
spontaneously adhered to VCAM-1 and ICAM-1, suggesting that
VLA-4 and LFA-1 integrins expressed on CD133! cells were, in
part, already activated and able to bind their counter ligands
without chemoattractant stimulation. Interestingly, the number of
cells spontaneously adherent to VCAM-1 was 178( 28, which
was more than 10 times greater than the number of cells that
adhered to ICAM-1 (15.7 ( 3.1), showing that nonactivated
CD133! cells displayed higher binding activity of VLA-4 than
LFA-1. Stimulation with MIP3& improved significantly the num-
ber of adherent cells to VCAM-1, and, though the number of
adherent cells remained low, an increase was also observed in
ICAM-1 (Figure 2A). Taken together, these results suggest that
Figure 1. FACScan immunophenotyping of sorted human circulating CD133! and CD133# cells. Human circulating CD133! cells obtained from the peripheral blood of
healthy donors were characterized after FACSVantage sorting for the expression of adhesion molecules and chemokine receptors. The expression of the adhesion molecules
was also evaluated in sorted CD133" cells and after stimulation of sorted CD133! cells with 5 ng/mL TNF-#. CD133! cells (99% ( 1%) coexpressed CD44 and LFA-1. In
particular, we observed 2 subpopulations of CD133 on the basis of LFA-1dim and LFA-1bright expression. In addition, 83% ( 2% of CD133! cells expressed PSGL-1, 44% ( 3%
expressed VLA-4, and 60% ( 5% expressed L-selectin. Analysis of chemokine receptors showed a very low expression of CXCR3 and CXCR4 (4% ( 3%), whereas
44% ( 5.4% of CD133! cells were positive for CCR7. Less than 2% of total CD133! cells expressed CCR3 (1.6% ( 1.3%) or CCR5 (1.7% ( 1.5%). We observed that sorted
CD133" cells expressed 98% ( 1% CD44, 87% ( 1% LFA-1, 63.5% ( 1% L-selectin, 53.5% ( 1% CCR7, 19% ( 1% CXCR3, 3.5% ( 1% CXCR4, 1.2% ( 1% CCR3, and
0.09% ( 1% CCR5. Very low expression of VLA-4 (0.6% ( 0.5%), CCR3 (1.2% ( 1%), and CCR5 (0.09% ( 1%) was observed. After cytokine stimulation of sorted CD133!
cells, the expression of L-selectin decreased from 60% to 4%. The other adhesion and chemokine molecules showed similar decreases.
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CD133! cells preferentially adhere in vitro using VLA-4 integrin.
To demonstrate specificity, the assays were performed in the
presence of anti–VCAM-1 and anti–ICAM-1 antibodies (R&D
Systems), and the blockade of binding was greater than 95% (data
not shown). We also performed flow cytometry assays using E- and
P-selectin chimeras on the sorted CD133! and CD133" fractions
of blood-derived mononucleated cells. Results demonstrated that
approximately 40% of human CD133! cells bound to E-selectin,
whereas approximately 10% of these cells bound to P-selectin.
These results suggested that unstimulated CD133! cells expressed
functional ligands mainly for E-selectin (Figure 2B). Moreover, the
binding of CD133" cells for E- and P-selectin was, respectively,
1.1%( 0.3% and 1.9%( 0.2% (Figure 2C), showing that these
cells displayed low binding activity of PSGL-1.
In vivo staining of adhesion molecules in dystrophic vessels
To support the results obtained with binding assays, we performed
an in vivo staining study aimed at identifying the endothelial
adhesion molecules potentially involved in dystrophic muscle
homing. For this reason, scid/mdx mice were monitored in basal
conditions (n' 5), after 1 hour of swimming exercise (n' 5), and
after intravenous injection of 1 %g TNF-# (n ' 5). Through the use
of fluorescent antibodies and intravital microscopy, we observed
that vessels of 3-month-old scid/mdx mice were positive for the
expression of P-selectin, whereas MAdCAM-1, ICAM-1, and
E-selectin were not detected. Positivity for anti–ICAM-1 and
anti–MAdCAM-1 antibodies was found in Peyer patches, as
expected. P-selectin–positive vessels were visible in pectoral and
hind limb muscles with tortuous morphology and regions of
narrowing, and very low expression of VCAM-1 was observed in
some vessels. After stimulation with TNF-# and 24 hours after
muscle exercise, no variation in the expression of E-selectin and
MAdCAM-1 was observed, whereas VCAM-1 in vivo staining
showed an increase in the number of positive vessels and an
enhanced intensity of the positive vessels (Figure 3). Surprisingly,
and in contrast to the VCAM-1 results, ICAM-1 expression was not
up-regulated in dystrophic muscle after TNF-# injection, though in
the same animals we found positivity for ICAM-1 in Peyer patches
and brain. No detectable differences were observed between
arteriolar and venular staining. In vivo staining performed with
a control mAb anti–human Ras showed no in vivo staining of
dystrophic muscle (data not shown). In vivo staining data were
confirmed by immunofluorescence for CD31 and #SMA per-
formed on cryosections of perfused mice. It was, in fact,
possible to detect several CD31! muscle venules and #SMA-
positive arterioles that coexpressed P-selectin or VCAM-1
(Figure 3) in the cryosections obtained from the same muscles
previously monitored by in vivo staining.
Intravital microscopy performed in dystrophic muscle vessels
Muscle homing and vascular adhesion properties of CD133! cells
were next verified in the pectoral and gastrocnemius muscles of
3-month-old scid/mdx mice under flow conditions. For all in vivo
experiments, we used blood-derived CD133! cells obtained with
magnetic column separation. Even if the purity obtained with this
method was just greater than 90%, the contaminating fraction of
CD133" cells did not affect our results. In fact, the characterization
of adhesion molecules and the adhesion assays of sorted CD133"
cells showed a low capacity of these cells to interact with the main
endothelial adhesion molecules involved in the recruitment from
the bloodstream described in our experiments. When injected into
the aortic arch (through the right carotid), few human CD133! cells
were able to firmly adhere to the murine muscle vessels, but most
interacting cells performed rolling (21( 5.4 for rolling interac-
tions and 0.8( 0.3 for firm adhesion; mean( SEM). We observed
that some cells were mechanically trapped in blood capillaries and
in proximity to narrowing vessels. This low capacity of CD133!
cells to firmly adhere to the dystrophic vessel endothelium
probably resulted because the expression of P-selectin, as a rolling
receptor, in the muscle vessels of scid/mdx was insufficient to
mediate adhesion interactions necessary for efficient firm arrest.
We thus extended these experiments injecting the CD133! cells in
scid/mdx mice, which, after 1 hour of swimming exercise, dis-
played increased expression of VCAM-1. Rolling events were
more frequent (increase of 50%; P ) .04) in vessels stimulated
with exercise than in vessels in basal condition (31.5( 3.6)
(Figure 4E). We also analyzed the quality and strength of rolling by
measuring the rolling velocities (Vrolls) of interacting human
CD133! cells (Figure 4F). Median Vroll in basal conditions and
after swimming was 49.9 %m/s and 24.9 %m/s, respectively. In
addition, the distribution of Vroll in velocity classes showed a
larger number of cells with higher Vroll under basal conditions,
suggesting that different molecular mechanisms might mediate
rolling interactions after swimming compared with basal condi-
tions. Importantly, we observed a 6-fold increase in the number of
Figure 2. CD133! cells express functional adhesion molecules and CCR7
receptor. We evaluated the functionality of adhesion molecules expressed by
CD133! cells with in vitro adhesion assays on their ligands, and we tested the effect
of chemokines on this binding (A). Unstimulated CD133! cells adhered to human
VCAM-1 in vitro. This binding was improved by stimulation with CCR7 ligand MIP3&.
Only a reduced number of cells adhered to human ICAM-1, and a chemokine
response to stimulation led to increased cell adhesion. Adhesion was completely
absent in uncoated wells and extremely low in wells coated with FCS (background
adhesion). Results are expressed as mean ( SD of adherent cells per 0.2 mm2. The
number of spontaneously adhered cells was compared with the number of cells that
adhered after stimulation with CCL19 by using 2-tailed Student t test. *P ) .01;
**P ) .001. The functionality of PSGL1 was evaluated with a cytofluorimetric assay;
40% of CD133! cells were able to bind E-selectin, but only 10% were able to bind
P-selectin (B). CD133" showed very low ability to bind E- and P-selectin (1.1% ( 0.3%
and 1.9% ( 0.2%, respectively) (C).
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Figure 3. Characterization of endothelial adhesion
molecules in scid/mdx mice. Adhesion molecule expres-
sion on the endothelium of dystrophic muscle was evalu-
ated with the use of in vivo staining followed by observa-
tion with intravital microscopy and on cryosections before
and after TNF-# stimulation or muscle exercise. Fluores-
cein-protein (F/P) ratios for mAbs were 3.0 for anti–E-
and anti–P-selectin mAbs, 3.2 for anti–ICAM-1 mAb, 2.9
for anti–MAdCAM-1 mAb, and 3.4 for anti–VCAM-1 mAb.
An anti–human Ras mAb was used as control and had an
F/P ratio of 3.6 (data not shown). Murine vessels of
scid/mdx mice expressed P-selectin in basal condition as
shown by in vivo staining. Moreover, after muscle exer-
cise and TNF-# stimulation, we registered significant
improvement in the number of vessels expressing P-
selectin and VCAM-1. In vivo staining data were con-
firmed by immunofluorescence staining showing the ex-
pression of P-selectin or VCAM-1 (in red) but not
E-selectin, MadCAM-1, or ICAM-1 in CD31! venules
(shown in the middle line of each condition), #SMA–
positive arterioles (shown in the lower line of each
condition), or murine muscle vessels (both in green).
DAPI-positive nuclei are shown in blue. Vessels were
acquired at $40 magnification. Scale bars represent 100
%m for intravital microscopy (black-and-white images)
and 10 %m for immunostaining (color images).
Figure 4. Intravital microscopy. Human circulating CD133! cells injected in the dystrophic scid/mdx mice firmly adhered in dystrophic muscle vessels (A-D). To improve
contrast between the intravascular and extravascular compartment, the animals were injected intravenously with low doses of FITC-dextran. Labeled cells (bright dots
indicated by arrows) can be seen in muscle vessels a few minutes after intra-arterial injection under basal conditions (A-B). After muscle exercise, it was possible to observe
significant improvement in the number of cells (white dots) that firmly adhered in venules of different diameters and apparently also in capillaries of scid/mdx mice (C-D). The
behavior of fluorescently labeled CD133! cells was studied under basal conditions and after swimming (E). Ten venules per 4 animals were studied under basal conditions, and
8 venules per 4 animals were studied after swimming. Data are expressed as mean ( SEM. Hemodynamic parameters (mean ( SD) are as follows: D ' 46 ( 11 %m;
Vm ' 872 ( 42 %m/s; WSR ' 157 ( 33 s"1; WSS ' 3.9 ( 0.8 (dyn/cm2) in mice studied under basal conditions and D ' 37 ( 13 %m; Vm ' 810 ( 56 %m/s;
WSR ' 177 ( 44 s"1; WSS ' 4.4 ( 0.9 (dyn/cm2) in mice studied after swimming. Velocity histograms were generated by measuring rolling velocity (F). Frequency
distributions were calculated after cells were assigned to velocity classes from greater than 0 %m/s to 5 %m/s, 5-10 %m/s, 10- 20 %m/s, and so on. To quantify the enhancement
of rolling induced by overexpression of VCAM-1 by muscle vessels, we evaluated the behavior of CD133! cells in the same animal on the same vessel in 2 steps: after exercise
and after treatment with anti–VCAM-1. Cells were injected before anti–VCAM-1 mAb administration (G). Then mice received 100 %g mAb intravenously, and, after 10 minutes,
we injected the same number of cells as for the control. Five venules were examined per 3 mice. Bars depict rolling and arrest fractions as percentages of control cells that
rolled and arrested in the same venule. Data are expressed as the mean ( SEM. Groups were compared by using 2-tailed Student t test. Hemodynamic parameters
(mean ( SD) were D ' 28.7 ( 7 %m; Vm ' 599 ( 177 %m/s; WSR ' 174 ( 69 s"1; WSS ' 4.3 ( 1.7 (dyn/cm2) during the injection of control cells and D ' 28.7 ( 7 %m;
Vm ' 555 ( 87 %m/s; WSR ' 161 ( 50 s"1; and WSS ' 4 ( 1.2 (dyn/cm2) after injection of anti–VCAM-1 mAb. (H) Velocity histograms before mAb administration and after
anti–VCAM-1 mAb injection were generated as in panel F. Scale bars represent 100 %m. *P ) .01; **P ) .04.
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CD133! cells able to firmly adhere in capillaries, small postcapil-
lary venules, and larger venules (5.5( 1.9) (Figure 4E). The
increased recruitment after swimming could be explained by the
natural capacity of CD133! cells to bind VCAM-1 because of the
presence on their membrane of the integrin very late antigen
(VLA-4). Taken together, these results show that the activation of
dystrophic vessel endothelium by exercise improves the adhesion
of human CD133! cells in vivo.
We next sought to identify the molecular mechanisms of
rolling and arrest in dystrophic muscle venules after swimming.
Rolling interactions were not inhibited after the administration
of anti–VCAM-1 mAb. In contrast, almost 60% of firm adhesion/
arrest was blocked by the use of anti–VCAM-1 mAb (Figure
4G). Median Vroll was 23.8 for control cells and 24.5 after
anti–VCAM-1 administration. However, though not statistically
significant, the mean ( SD value of Vroll was slightly increased
after VCAM-1 blockade: 31 ( 21 for control cells compared
with 39 ( 42 after mAb blockade. In addition, the distribution
of Vroll in velocity classes showed a slightly larger number of
cells with higher Vroll after the administration of anti–VCAM-1
mAb (Figure 4H), suggesting that VCAM-1 might contribute to
roll strengthening of some CD133! cells. An isotype-matched
control antibody (anti–human Ras) had no effect on rolling or
arrest (data not shown). These results clearly show an important
role for VCAM-1 in the recruitment of CD133! cells in
dystrophic muscle after muscle exercise. Hemodynamic param-
eters for intravital microscopy experiments are depicted in
Figure 4E,G.
Detection of intra-arterially injected CD133! stem cells
by fluorescence and microfil perfusion
To confirm the results obtained by intravital microscopy and
quantify firmly adhered cells with a different method, animals
injected intra-arterially with CD133! stem cells were perfused
with microfil. This technique offers the possibility of eliminat-
ing transient adhered cells, observing the 3-dimensional cast of
dystrophic muscle vessels, and identifying injected cells distri-
bution in toto.
In basal conditions, the transillumination of microfil-perfused
vessels of intra-arterially injected scid/mdx mice rarely showed
PKH2 CD133!-labeled cells in large and small vessels of dystro-
phic muscles (2( 1.41 cells/field at 20$ magnification) (Figure
5A, C). In contrast, after muscle exercise, we observed a 4- to
5-fold increase of the number of adhered cells in large vessels and
distributed in the capillary network (10( 2.51 cells/field at 20$
magnification; P ) .01) (Figure 5B, D-E).
MRI analysis
To test the migration capacity of human circulating CD133!
stem cells and to monitor the fate of implanted cells using a
noninvasive method such as MRI, we labeled these cells with a
contrast agent based on dextran-coated superparamagnetic iron
oxide nanoparticles clinically approved as a blood pool agent
(Endorem; Guerbet). In vitro results demonstrated that CD133!
stem cell iron incorporation leads to MRI visualization. The iron
oxide nanoparticles in cultured CD133! stem cells were ob-
served as blue spots after Prussian blue staining (Figure 6F-G).
Cell counting of Prussian blue–stained cells revealed that after
12 hours of labeling with Endorem (Guerbet), the percentage of
labeled cells was 44.2% ( 7.4% and that after 24 hours of
labeling, the percentage was increased to 85.6% ( 8.3%. Longer
labeling did not increase either the number of labeled cells or the
number of iron particles inside the cells. A colorimetric assay for
the quantification of cell proliferation and cell viability based on
the cleavage of the tetrazolium salt WST-1 (Roche Molecular
Biochemicals, Indianapolis, IN) by mitochondrial dehydroge-
nases in viable cells did not show any differences between
nanoparticle-labeled and nonlabeled cell groups. Moreover,
MRI images showed a clear hypointense signal at all concentra-
tions of more than 500 cells (Figure 6A-E). At 24 hours after
intra-arterial transplantation, we observed a hypointense signal
obtained by MRI evaluation in the quadriceps, tibialis anterior,
and soleus muscle tissues. No recognizable hypointense signal
in the muscle of uninjected leg was detected. The hypointense
signal in muscle remained visible during the first 24 hours after
intra-arterial injection with no change in shape. The histology of
these hypointense areas showed that a large number of Prussian
blue–positive cells had entered into the muscle and that most of
them coexpressed the CD133 antigen around vessels, suggesting
migration from the arterial circulation (Figure 6I, J).
Figure 5. Evaluation of the effect of muscle exercise on the recruitment of
human CD133! cells. CD133! stem cells were incubated with PkH2 green to allow
detection by fluorescence microscopy with a perfusion technique that showed the
vasculature in 3 dimensions. Intra-arterially injected CD133! stem cells were rarely
found in the vessels of dystrophic muscles before exercise (A, C). In contrast, after
swimming exercise intra-arterially injected scid/mdx mice showed an increased
number of adhered cells in the capillary network (B, D) and to large vessels (E). (E)
Large vessels perfused with a rubber silicon fluid were detected in transillumination.
(inset) Cells were not evident in other fluorescence acquisitions, confirming that
positively registered cells in vessels were not artefacts. (F) Statistical evaluation by
Student t test of the number of CD133! cells adhered to the vessel and confirmed
significant improvement in recruitment after exercise. *P ) .05. Scale bars represent
100 %m (A-C), 200 %m (D), and 25 %m (E). In panels A-E, arrows indicate the labeled
cells. Error bars in panel F indicate standard deviation.
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In vitro labeling of CD133! stem cells with 99mTc-labeled
HMPAO and evaluation of labeled cell accumulation
in dystrophic scid/mdx mice
To test the efficiency of labeling, CD133! stem cells were
incubated with 15 MBq HMPAO in serum-free RPMI between
30 and 120 minutes. A time-dependent incorporation of HMPAO
was observed with maximum efficiency after 60 minutes,
resulting in an overall labeling efficiency of 61% ( 11%. Next,
we investigated whether the labeling affected cell viability or
function. Up to 120 hours after HMPAO labeling, trypan blue
uptake in the radiolabeled CD133! stem cells was not signifi-
cantly different from that in controls, with 97.1% ( 2.1% of
cells trypan blue negative after labeling (n ' 3). The viability of
labeled CD133! cells was also confirmed by cytofluorimetric
analysis. In fact, annexin V and PI staining showed a vitality of
97% ( 2% (Figure 7A). Similarly, the functional capacity of
CD133! stem cells to migrate in response to vascular endothe-
lial growth factor in a modified Boyden chamber assay was not
affected by radiolabeling when radiolabeled CD133! stem cells
were compared with their unlabeled controls (data not shown).
To determine the leakage of HMPAO into the supernatant, we
checked the activity of HMPAO in the supernatants and in the
adherently growing CD133! stem cells. We found that
32.4% ( 5.2% of the HMPAO incorporated into CD133! stem
cells was retained after 24 hours (data not shown). We thus
investigated the distribution of radioactively labeled human
CD133! stem cells after their intra-arterial injection into
scid/mdx mice. In these experiments, we compared the distribu-
tion of radioactivity obtained after the injection of CD133! cells
in exercised mice pretreated with anti–ICAM-1 (n ' 4) or
anti–VCAM-1 (n ' 4) or without pretreatment (n ' 5). As
control, we characterized the radioactivity distribution obtained
after intra-arterial injection of radiolabeled CD133" cells in
basal condition (n ' 5) and after exercise (n ' 5). Twenty-four
hours after the injection of CD133! cells, a high tracer
accumulation was found in muscle tissues of mice without
pretreatment (70.1% ( 18.3% of the injected activity). The
muscle tracer distribution did not show major changes after
anti–ICAM-1 mAb pretreatment (71.2% ( 9.1% of whole body
activity). However, we observed reduced accumulation of
CD133! cells in other organs, such as the spleen, in which it is
known that the blood vessel endothelium expresses ICAM-1. In
contrast to the results obtained with anti–ICAM-1 antibody, we
registered a marked reduction (approximately 10-fold) of the
radioactivity in the muscle of dystrophic mice pretreated with
anti–VCAM-1 mAb (Figure 7B). The specific radioactivity in
isolated muscles after swimming exercise and no pretreatment
compared with anti–ICAM-1 pretreatment were, respectively,
68 047.9 ( 5048.36 cpm/g tissue and 90 337.1 ( 6874.11 cpm/g
tissue. After anti–VCAM-1 pretreatment, specific total muscle
activity decreased significantly to 8152.4 ( 1507.36 cpm/g
(P ) .05). All these data suggest a critical role of VCAM-1 in
the recruitment of CD133! stem cells in exercised dystrophic
muscle tissues. However, an important interaction was observed
in control mice injected with CD133" cells. In fact, the
radioactivity detected after the injection of these labeled cells
was 79 721.5 ( 1060.66 cpm/g tissue in basal condition, whereas
a decrement of 3-fold (to 31 533 ( 1342.07 cpm/g tissue)
was observed after exercise. These data demonstrate that the
improvement observed in the recruitment of radiolabeled cells
after swimming exercise is related to the CD133! fraction, and
these observations are not affected by the contaminating nega-
tive cells.
Human dystrophin expression in injected scid/mdx mice
We then investigated the in vivo ability of CD133! stem cells to
differentiate into the myogenic lineage after intra-arterial injec-
tion. As shown by radioactivity studies to contain donor cells,
Figure 6. T2-weighted images of phantoms and injected
muscle leg tissues and implanted CD133! stem cells. MR
images of phantoms formed by a set of test tubes containing a
suspension of Endorem-labeled cells in gelatin: (A) 500, (B) 5000,
(C) 20 000, (D) 50 000, and (E) 100 000 cells. Sample contains
gelatin only. Inhomogeneities in the phantom images were caused
by the moderate sedimentation of cells while the gelatin was
setting. Sequence parameters were repetition time (TR), 2000
msec; effective echo time (TE), 42.5 msec; turbo factor, 4; number
of acquisitions (AC), 16; field of view (FOV), 3.5 cm; matrix,
256 $ 256; slice thickness, 0.5 mm; slice separation, 1 mm. Two
sets of interleaved transversal images were measured to cover
the whole muscle. For in vitro experiments, phantoms of sterile
agarose 2% containing labeled cells were measured by a similar
sequence with different geometry: FOV, 6 cm; matrix, 256 $ 256;
slice thickness, 1 mm. Only one slice was measured for phan-
toms. Prussian blue staining of samples containing 50 000 (F) and
100 000 (G) cells. (H) Several areas of hypointense signal were
seen 24 hours after intra-arterial grafting by MRI (white quadrant).
(J) Histologic examination performed on biopsy specimens of
MRI-positive areas confirmed positive Prussian blue–stained cells
that coexpressed the CD133 antigen around muscle vessels.
Scale bars represent 100%m (A-E); 25%m (F-G, I, inset); 3 mm (H).
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tissues were evaluated for the expression of human dystrophin 2
months after CD133! stem cell engraftment. Human dystrophin–
positive myofibers were counted in 5 nonadjacent cross-sections
of the intra-arterially injected muscles, and the longitudinal
dimension of the positive area was approximately 600 %m. In
unexercised animals that received intra-arterial injection, we
observed that the highest number of dystrophin-positive fibers
per cross-section was detected in the quadriceps muscle of the
injected leg (roughly 0.5% to 1.0% of total fibers in a given
cross-section) (Figure 7E; Table 1). However, after muscle
swimming/exercise, the percentage of human dystrophin in-
creased 4-fold in all observed muscle tissues of the injected leg
(Figure 7F; Table 1). In all injected muscles, many of the human
dystrophin–positive fibers expressed the anti–human lamin A/C
(Figure 7C-D). Moreover, human dystrophin–positive myofibers
were clustered primarily near #SMA-positive muscle arteries
(Figure 7E-F). Indeed, positive human lamin A/C cells were found
near the human dystrophin–positive myofibers. All these data
suggest that muscle exercise increases the number of mature
myofibers expressing the human dystrophin after the intra-arterial
transplantation of blood-derived CD133! stem cells.
Discussion
Recently we demonstrated that human circulating cells express-
ing the CD133 antigen behave as a stem cell population capable
of commitment to hemopoietic, endothelial, and myogenic
lineages.1 The discovery of the mechanisms involved in the
muscle homing of stem cells will aid in improving a potential
therapy for muscular dystrophy based on the systemic delivery
of such stem cells.
Almost all CD133! cells coexpressed CD44 and LFA-1, with a
particular distribution of the latter antigen in 2 subpopulations,
LFA-1dim and LFA-1bright, suggesting the existence of a less
activated and a more activated subpopulation of CD133! cells.
More than 40% of the CD133 cells expressed PSGL-1, VLA-4,
L-selectin, and CCR7, suggesting that part of CD133! cells might
migrate in secondary lymphoid organs.11 Moreover, the expression
of these chemokine receptors and adhesion molecules of CD133!
cells do not seem to be particularly influenced by exposure to
TNF-#. All these data demonstrate that freshly isolated human
CD133! cells already express a pattern of adhesion molecules
potentially able to mediate migration through the blood vessel wall.
Thus, we investigated the ability of stem cells to bind endothelial
adhesion molecules such as ICAM-1, VCAM-1, P-selectin, and
E-selectin using in vitro functional assays. The results obtained
suggest that VLA-4 and LFA-1 integrins expressed by CD133!
cells are functional, at least in part, and are able to spontaneously
bind VCAM-1 and ICAM-1, respectively. However, we observed
that the capacity of VLA-4 to bind VCAM-1 was more than 10-fold
higher than the capacity of LFA-1 to bind ICAM-1, suggesting that
CD133! cells might preferentially migrate using VLA-4. In
addition, unstimulated CD133! cells express functional ligands for
Figure 7. HMPAO-labeled CD133! cells and measurement of the distribution of radioactivity by $-counter in dystrophic injected mice. (A) Viability of radiolabeled
cells. Flow cytometry analysis with PI and annexin V confirmed the 97% viability observed with trypan blue staining. (B) When we blocked the VCAM-1 molecule with the
anti–VCAM-1 antibody, we obtained a significant decrease in radioactivity 12 hours after intra-arterial injection in the muscles and in the different organs, such as brain, lungs,
kidneys, spleen, and liver, compared with values obtained from untreated scid/mdx mice. A decrement in radioactivity in organs of mice treated with anti–ICAM-1 was also
detected, whereas in the muscle we registered a significant improvement in counts per minute per gram. Animals injected with CD133" cells used as control showed a
decrement in the recruitment of intra-arterial injected cells after exercise (C-F). Human dystrophin expression 60 days after intra-arterial injection of human CD133! stem cells
is shown. Error bars indicate standard deviation. (C-D) Colocalization of the human dystrophin (red), human lamin A/C nuclei (green), and Hoechst (blue) demonstrated the
formation of normal human myofibers in dystrophic muscles after transplantation of the human blood–derived CD133! cells. The number of human dystrophin–positive
myofibers in quadriceps of exercised mice (D, F) was higher than muscle of unexercised mice (C, E). Low magnification revealed mature human dystrophin muscle fibers (red)
near #SMA-positive muscle arteries (green) after the intra-arterial transplantation of CD133! stem cells into unexercised (E) and exercised (F) dystrophic scid/mdx mice. Scale
bars represent 100 %m (C), 75 %m (D), and 50 %m (E-F).
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E-selectin, but not for P-selectin, suggesting preferential binding to
E-selectin during rolling interactions in vivo. Using intravital
microscopy, it was possible to characterize the expression of
murine endothelial adhesion molecules potentially involved in
dystrophic muscle homing. Unexpectedly, some blood vessels of
scid/mdx mice in basal conditions were positive for the expression
of P-selectin, whereas MAdCAM-1, ICAM-1, and E-selectin were
not detected. Very low expression of VCAM-1 was detected on
some vessels. Moreover, when injected into the circulation of
scid/mdx mice, few human circulating CD133! cells were able to
firmly adhere to the murine muscle vessels. In fact, CD133! cells
bind only E-selectin, but not P-selectin, chimera, whereas dystro-
phic muscle vessels express P-selectin but not E-selectin. This lack
of matching between endothelium and CD133! cells may explain
the low capacity of stem cells to interact with the blood vessel wall
in dystrophic muscles. P- and E-selectin on endothelial cells are
primary adhesion molecules for capture and the initiation of
rolling.12 E- and P-selectin rolling was previously described for
hematopoietic progenitor cells (HPCs) in bone marrow vessels.3
Selectin-independent rolling of HPCs can be also mediated by
#4-integrins, which interact with endothelial VCAM-1.3 However,
constitutive expression of P-selectin and very low expression of
VCAM-1 in some dystrophic vessels were not sufficient to mediate
efficient recruitment of CD133! cells in our experimental models.
After treatment of animals with TNF-# or after swimming muscle
exercise, E-selectin and MAdCAM-1 expression were not up-
regulated in dystrophic muscle vessels, whereas a massive increase
in the expression of VCAM-1 was observed. Surprisingly, and in
contrast to VCAM-1 data, ICAM-1 expression was not up-
regulated in dystrophic muscle, though in the same animals we
found positivity for anti–ICAM-1 mAb in Peyer patches and brain.4
Abnormal P-selectin expression in dystrophic muscle and the lack
of ICAM-1 and E-selectin up-regulation after TNF-# administra-
tion support the hypothesis that dystrophic muscle might represent
a unique milieu able to selectively recruit blood cells expressing
peculiar combinations of adhesion molecules. Intravital micros-
copy performed in the dystrophic vessels of scid/mdx mice,
enriched in VCAM-1 and P-selectin after exercise, showed an
increase in the number of cells able to roll and firmly adhere. The
lack of E-selectin expression on scid/mdx endothelium and the lack
of binding of P-selectin chimera by CD133! cells suggest that
rolling events and firm arrest of human stem cells in dystrophic
muscle vessels might have been mediated by VCAM-1 and VLA-4
in our experimental models. By using CD133! cells labeled with
nanoparticles of iron oxide and MRI, it was possible to demonstrate
the presence of migrated stem cells into the muscle after intra-
arterial injection. In addition, muscle swimming exercise increased
the percentage of human dystrophin–positive myofibers by 4-fold
in all observed muscle tissues, documenting that exercise increases
the recruitment of CD133! cells into the dystrophic muscle. The
increase of CD133! recruitment after exercise was also confirmed
by microfil perfusion. To demonstrate the importance of VCAM-1
in the recruitment of human circulating CD133! cells, we per-
formed blocking experiments with radiolabeled cells. We regis-
tered a marked reduction of approximately 10-fold in the radioactiv-
ity in the muscle of dystrophic mice injected with anti–VCAM-1
mAb before CD133! cell administration. These results clearly
demonstrate that VCAM-1 blockade prevented CD133! accumula-
tion in the dystrophic muscle and that the VCAM-1/VLA-4
adhesion receptor pair has a critical role in the recruitment of stem
cells to dystrophic muscle vessels. Our results are supported by
recent studies showing that VCAM-1 acts as an “endothelial
homing molecule” with a role in the recruitment of stem cells in
Table 1. Blood-derived CD133! cells yield human Dys3! myofibers within injected dystrophic muscles after intra-arterial
transplantation of unexercised and exercised scid/mdx mice
Positive myofibers
Quadriceps Soleus Tibialis anterior
Unexercised Exercised Unexercised Exercised Unexercised Exercised
Mouse 1
Lamin A/C! 11 ( 3 45 ( 1* 7 ( 5 52 ( 3* 4 ( 2 32 ( 1*
Dys! fibers/s 26 ( 13 73 ( 5* 14 ( 9 61 ( 10* 10 ( 2 55 ( 11*
Dys/lamin A/C! fibers 15 ( 61 45 ( 1* 9 ( 6 47 ( 7* 5 ( 8 32 ( 22*
Mouse 2
Lamin A/C! 10 ( 8 35 ( 10 15 ( 2 21 ( 14 7 ( 3 37 ( 5*
Dys! fibers/s 12 ( 5 59 ( 9* 9 ( 2 48 ( 11* 18 ( 11 91 ( 32*
Dys/lamin A/C! fibers 9 ( 3 45 ( 4* 3 ( 1 27 ( 12* 9 ( 7 72 ( 18*
Mouse 3
Lamin A/C! 24 ( 11 101 ( 17* 10 ( 7 70 ( 24* 17 ( 4 33 ( 13
Dys! fibers/s 16 ( 11 68 ( 11* 6 ( 2 49 ( 16* 14 ( 10 46 ( 7*
Dys/lamin A/C! fibers 8 ( 3 44 ( 12* 3 ( 1 31 ( 21* 8 ( 2 29 ( 13*
Mouse 4
Lamin A/C! 19 ( 6 36 ( 19 8 ( 5 24 ( 8 15 ( 7 53 ( 11*
Dys! fibers/s 10 ( 6 61 ( 21* 4 ( 3 41 ( 13* 9 ( 8 57 ( 31*
Dys/lamin A/C! fibers 7 ( 4 51 ( 15* 1 ( 2 35 ( 20* 2 ( 1 31 ( 16*
Mouse 5
Lamin A/C! 18 ( 9 81 ( 21* 10 ( 4 72 ( 12* 11 ( 4 43 ( 23*
Dys! fibers/s 20 ( 11 89 ( 22* 9 ( 1 53 ( 12* 14 ( 11 61 ( 15*
Dys/lamin A/C! fibers 7 ( 3 67 ( 19* 5 ( 3 26 ( 8* 5 ( 3 37 ( 25*
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inflamed central nervous system.13 However, further studies are
needed to enhance the migratory ability of CD133! cells and to
understand other mechanisms of stem cell homing, such as
chemokines and chemokine receptors controlling integrin activa-
tion, leading to arrest in dystrophic vessels and chemotaxis in the
damaged muscle. In conclusion, our results show that the induction
of VCAM-1 expression on the dystrophic muscle endothelium
represents a key mechanism of delivery of CD133! cells, allowing
for improvement in potential therapy for muscular dystrophy based
on the intra-arterial administration of stem cells.
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